Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3007113 · 1 trial · 1 indication
Data presented are the number of participants who experienced at least one treatment emergent adverse event (TEAE). A TEAE is defined as an event that first occurred or worsened after randomization. A summary of serious AEs and all other non-serious AEs, regardless of causality, is located in the Reported Adverse Event module.
| Arm | Type | Description |
|---|---|---|
| LY3007113 | EXPERIMENTAL | Study has a dose escalation phase (Part A) and dose confirmation phase (Part B). Participants in the dose escalation phase will receive 1 of 6 doses of LY3007113 administered orally every 12 hours for at least one cycle. Participants in the dose confirmation phase will receive the maximum tolerated dose from the dose escalation phase administered orally every 12 hours for at least 1 cycle. Three days prior to the start of the first cycle, participants will receive 1 dose at their assigned level to allow for the collection of single dose pharmacokinetics. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met. |
| Name | Type | Description |
|---|---|---|
| LY3007113 | DRUG | Administered orally |
Inclusion Criteria: * Have histological or cytological evidence of a diagnosis of cancer that is advanced and/or metastatic for which available standard therapies have failed to provide clinical benefit for their disease * For Dose Escalation (Part A): cancer, either a solid tumor or a lymphoma * F...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
LY3007113 is an investigational small molecule being studied for the treatment of metastatic cancer. It was evaluated in a Phase 1 clinical trial in participants with advanced cancer. The drug is not approved and remains in clinical development.
LY3007113 is being developed by Eli Lilly and Company, traded on the New York Stock Exchange under the ticker LLY. The company sponsored a Phase 1 clinical trial of the drug in patients with advanced cancer.
LY3007113 is in Phase 1 clinical development. A single Phase 1 trial of the drug has been completed. The drug is investigational and has not been approved for any use.
LY3007113 has been studied in one clinical trial, NCT01463631, titled "A Study of LY3007113 in Participants With Advanced Cancer." This Phase 1 trial was completed in the United States and enrolled 27 participants with metastatic cancer.
LY3007113 is not FDA approved. It is an investigational drug that has completed a Phase 1 clinical trial. The drug is still in clinical development and has not been authorized for marketing.